PRN: Payer Hotspots in Specialty & Oncology

07/mar/2016 15:10:09 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Payer Hotspots in Specialty & Oncology


DUBLIN, March 7, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Payer Hotspots in Specialty & Oncology" report to their offering.

This Payer Hotspots survey focuses on the potential areas for increased management in specialty and oncology pharmaceuticals. The survey was conducted in the 3rd Quarter of 2015. Each of the 10 respondents hold a Medical Director position at a major health plan and cumulatively represent 41 million covered lives. All 10 MD's engaged completed the entire survey.

The life expectancy of some CF patients, due to new and innovative therapies, has been extended to over 40 years. This, in and of itself, is a good thing! The vast majority of CF patients will be diagnosed by age 12 - the approved age for beginning Orkambi treatment.

If 5,500 (two-thirds of population size) patients continue treatment for their chronic disease from age 12 to 41 (ages of approved treatment and average life expectancy, respectively), we can expect therapy to last 29 years on average. Orkambi could potentially cost someone a total of $41 billion to treat this population over their lifespan - $7.5 million per patient.

Questions Answered:

  • Specialty & Oncology as current percentage of total drug spend
  • Top 3 areas of growth in Specialty (2-3 years)
  • Top 3 areas of growth in Oncology (2-3 years)
  • Estimated growth trend in Specialty (2-3 years)
  • Estimated growth trend in Oncology (2-3 years)
  • Current drivers of Specialty drug spending
  • Current drivers of Oncology drug spending

Companies Mentioned:

  • Abbvie
  • Amgen
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Teva

Report Structure:


About this Survey

Areas of Focus

Current Percentage of Total Drug Spend: Specialty

Average Expected Percentage Growth of Total Drug Spend: Specialty

Percentage of Current Specialty Spend: By Indication

Two- to Three-Years Estimated Growth: Specialty

Targeted Categories for Increased Management: Specialty

Current Percentage of Total Drug Spend: Oncology

Expected Percentage Growth of Total Drug Spend: Oncology

Largest Categories & Estimated Percentage of Oncology Spending

Top Areas of Oncology Spending Growth over the Next 2-3 Years

Top 3 Therapy Classes of Expected Growth: Oncology

Top 3 Categories of Growth: Rare Diseases

Parting Thoughts

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl